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ABSTRACT 
Background: The Carlos III Health Institute (Instituto de Salud Car­
los III - Spain) allocates funding to health research support in the Spanish 
National Health System (NHS). This study aimed to analyse the correla­
tion of health research fund allocations in the NHS and the burden of dise­
ase in Spanish population. 
Methods: Cross-sectional study. Burden of disease measures were 
calculated: disability-adjusted life-years (DALYs), years of life lost (YLLs) 
and mortality by cause. A correlation analysis (Spearman´s Rho) was 
applied to test the association between these measures and 2006/2007 health 
research funding. 
Results: Using disease categories (n=21), the correlation between 
funding and disease-burden measures is: DALY (r=0.72; p<0.001), morta­
lity (r=0.60; p=0.004) and YLL (r=0.56; p=0.008). By disease-specific sub­
categories (n=52): DALY (r=0.55; p<0.001), mortality (r=0.54; p<0.001) 
and YLL (r=0.55; p<0.001). Malignant neoplasms, neuropsychiatric condi­
tions, cardiovascular diseases and infectious and parasitic diseases receive 
the greater health research funding support. However, the higher funds 
allocated per DALY lost ratios were for blood and endocrine disorders, 
infectious and parasitic diseases and congenital anomalies. 
Conclusions: Our analysis suggests that NHS research funding is 
positive moderately high-associated with the burden of disease in Spain, 
although there exists certain disease’s categories that are over or 
under-funded in relation to their burden generated. In health planning, 
burden of disease studies contributes with useful information for setting 
health research priorities. 
Key words: Health priorities. Research support as topic. Health 
services research. Burden of illness. Disability-adjusted life years. DALY. 
Potential Years of Life Lost. PYLL. Mortality. 
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RESUMEN 
Relación en España entre la investigación sanitaria 
financiada por el Sistema Nacional de Salud 
y la carga de enfermedad en la comunidad 
Fundamento: El Instituto de Salud Carlos III destina parte de sus
presupuestos a la financiación de la investigación sanitaria en el ámbito
del Sistema Nacional de Salud (SNS). El objetivo del estudio es analizar 
el grado de correlación de la financiación de la investigación sanitaria en 
el SNS con el patrón de carga de enfermedad en la población española. 
Métodos: Estudio transversal. Se calculan los años de vida ajustados 
por discapacidad (AVAD), los años de vida perdidos (AVP) y la mortalidad 
por causa. Se realiza un análisis de correlación (Rho de Spearman) para 
examinar la asociación entre estas medidas y los fondos de investigación 
2006/2007. 
Resultados: Por categorías de enfermedad (n=21), la correlación 
entre la financiación y las medidas de carga de enfermedad es: AVAD (r=0,72; 
p<0,001), mortalidad (r=0,60; p=0,004) y AVP (r=0,56; p=0,008). A nivel de
subcategorías (n=52): AVAD (r=0,55; p<0,001), mortalidad (r=0,54; p<0,001)
 y AVP (r=0,55; p<0,001). Los tumores malignos, las enfermedades neuropsiquiá­
tricas, las cardiovasculares y las infecciosas y parasitarias son las causas con 
mayor partida presupuestaria asignada. Por otro lado, las enfermedades en-
docrinas y de la sangre, las infecciosas y parasitarias y las anomalías congéni-
tas reciben la mayor financiación por AVAD perdido. 
Conclusiones: Se observa la existencia de una asociación positiva 
moderada/alta de las medidas de carga de enfermedad con la financiación 
de la investigación, si bien existen categorías de enfermedad sobre o infrafinan­
ciadas en relación con la carga que provocan. En planificación sanitaria, 
la carga de enfermedad aporta información útil a los debates sobre 
establecimiento de prioridades en investigación. 
Palabras clave: Prioridades en salud. Apoyo a la investigación como asunto. 
Investigación en servicios de salud. Carga de enfermedad. Años de Vida 
Ajustados por Discapacidad. AVAD. Años Potenciales de Vida Perdidos. APVP. 
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INTRODUCTION 
Health research is a key instrument for 
bettering quality and expectancy of life of 
the population and therefore has to be 
promoted throughout the whole health 
system as one of the fundamental elements 
for its growth. In this sense, the Carlos III 
Health Institute (Instituto de Salud Carlos 
III – ISCIII), a national public research 
institution, has the responsibility of 
promoting and fostering health research in 
the Spanish National Health System (NHS)1 
and participates in its setting of priorities 
and planning. For slightly over 20 years 
now, ISCIII has allocated much of its 
funding to health research through different 
formulae that are currently included in the 
Spanish National Plans for Scientific 
Research, Development, and Technological 
Innovation (R&D&I)2, 3, instrument of the 
scientific and technological policy of the 
Spanish Central State Administration. Such 
encouragement of health research is done 
through subsidies and financial aid from 
public funds that the Health Research Fund 
(HRF) of ISCIII (Fondo de Investigación 
Sanitaria – FIS) grants annually. These 
grants are competitively awarded and 
public and private non-profit entities are 
eligible. 
In research, it is necessary to set 
priorities, just as in so many other activities 
in which one does not have enough 
resources so as to attain all possible 
objectives. The planning and priorities 
setting is done in order to try to orientate 
research efforts towards the health needs of 
the population as well as to adhere to the 
existing resources. The difficulties to 
decide on the allocation of public funds are 
tackled in the literature although several 
procedures to guide decision making and to 
inform debates on priorities are 
acknowledged4-6. Along these lines, since 
earlier editions, the national plans have been 
justifying the setting of priorities around 
health problems that would contemplate 
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from the molecular, genetic and 
pathophysiologic basis to the clinical 
phases of diagnosis and treatment as well 
as aspects of community and health 
services evaluation, preferably of those 
groups of entities whose social and health 
interest would be more relevant considering 
the studies of burden of disease and of 
personal equity2, 3. 
The burden of disease, whose indicator 
is the Disability-Adjusted Life Years 
(DALY), measures the health losses in the 
population that represent the fatal and non-
fatal consequences of diseases, injuries and 
risk factors associated to them7, 8. The 
advantage of using this summary measure 
of population health in health policy and 
planning is that it offers the possibility of 
compiling in just an indicator the set of 
epidemiological data of each disease 
(mortality, incidence, prevalence, duration, 
disability, severity), thus being useful to 
measure and compare the health of 
populations or social groups, to study the 
evolution of the health of a population or 
the magnitude of a health problem 
throughout time, or to use these results as an 
additional instrument in the definition of 
health priorities or even in the impact 
assessment of certain health interventions 
through the use of efficiency analysis 
techniques (e.g. cost-effectiveness or cost­
utility analyses)9, 12. 
In some international studies16-21 , the 
action of several institutions has been 
assessed in regards to the allocation of public 
resources to health research. An example of 
this was the investigation carried out by 
Gross and colleagues16, where they 
determined the extent to which the 
distribution of the funding allocated to the 
research of 29 conditions or specific diseases 
from U.S. National Institutes of Health (NIH) 
was associated to different measures of 
burden of disease. Because of the limited 
budgets for financing the research of diseases 
with different health, economic and social 
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burdens, the interest in this kind of analysis 
has progressively risen in the last decade as a 
systematic way of generating knowledge to 
orientate future research agendas8, 13. 
In this context, our goal in this study is to 
analyse the correlation between health 
research fund allocations in the NHS and the 
burden of disease in the Spanish population.
 METHODS 
We did a cross-sectional study calculating 
the burden of disease in the Spanish 
population and determining its correlation 
with the funds allocated to health research in 
the NHS ambit for the study of specific 
diseases. 
Calculation of the burden of 
disease in Spain 2006 
Following the criteria set by Murray & 
Lopez in the Global Burden of Disease 
study8 carried out by the World Health 
Organization (WHO), the World Bank and 
Harvard University, all diseases and injuries 
have been grouped in accordance with the 
Burden of Disease Classification (BDC) into 
3 broad cause groups: a) communicable, 
maternal, perinatal and nutrirional 
conditions; b) noncommunicable diseases; c) 
accidents and injuries. Each group of 
diseases is divided into 21 categories (table 
1) which, in turn, can be divided into several 
subcategories. Ill-defined causes and garbage 
codes have been redistributed following the 
algorithms proposed by Murray and Lopez8. 
DALYs attributable to each disease or 
injury are the result of adding the time of 
life lost due to premature death - Years of 
Life Lost (YLLs) – and the functional and 
well-being losses caused by disability and 
poor health - Years Lived with Disability 
(YLDs) – (table 2). 
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YLLs are calculated by multiplying the 
deaths in each group of age by the life 
expectancy at the time of death. The data of 
mortality by gender, age and cause for the 
year 2006 were taken from the anonymized 
microdata file of death records of the 
Spanish National Institute of Statistics 
(Instituto Nacional de Estadística – INE)14. 
Deaths were redistributed according to the 
BDC’s criteria. The life expectancy limit 
we used is defined in a standard life table 
which is widely used in the studies of 
burden of disease (Princeton West level 26 
modified)15. YLDs, on their part, are 
calculated by multiplying the incidence by 
the mean duration of the disease and by a 
value that weights the seriousness of the 
disability – 0 (full health) to 1 (death) 
scale–. 
In this study, as in others with similar 
characteristics16-25, we applied an indirect 
method of YLDs estimates measurement 
developed in the Global Burden of Disease 
project8 that requires the information 
corresponding to a reference population 
detailed by gender, age and cause for YLLs 
and YLDs, and the structure by gender and 
age of mentioned population, as well as the 
YLLs of the population whose burden of 
disease is to be calculated. For this, we took 
the European subregion with very low 
mortality (Euro-A) defined by the WHO26, 
to which Spain belongs. We used the 
information corresponding to the last 
estimation made by the WHO at the time of 
analysis28, applying the YLDs/YLLs ratio 
by cause, gender and age corresponding to 
the Euro-A subregion to the YLLs 
calculated directly for the Spanish 
population. For those causes that have very 
low mortality but high disability, in which 
the YLDs/YLLs ratio is very unstable, the 
followed method suggests to estimate the 
YLDs applying the YLDs rate of the 
reference population (Euro-A) to the 
population under study (Spain). 
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Table 1 
Burden of disease classification (n = 21 categories) 
Disease classification ICD-10 code 
10100. Infectious and parasitic diseases A00–B99, G00, G03–G04, N70–N73 
10200. Respiratory infections J00–J06, J10–J18, J20–J22, H65–H66 
10300. Maternal conditions O00–O99 
10400. Perinatal conditions P00–P96 
10500. Nutritional deficiencies E00–E02, E40–E46, E50, D50–D53, D64.9, E51–E64 
20100. Malignant neoplasms C00–C97 
20200. Other neoplasms D00–D48 
20300. Diabetes mellitus E10–E14 
20400. Endocrine and blood disorders D55–D64 (minus D64.9), D65-D89, E03–E07, E15–E16, E20–E34, E65–E88 
20500. Neuropsychiatric conditions F01–F99, G06–G98 
20600. Sense organs disorders H00–H61, H68–H93 
20700. Cardiovascular diseases I00–I99 
20800. Respiratory diseases J30–J98 
20900. Digestive diseases K20–K92 
21000. Diseases of the genitourinary system N00–N64, N75–N98 
21100. Skin diseases L00–L98 
21200. Muskuloskeletal diseases M00–M99 
21300. Congenital anomalies Q00–Q99 
21400. Oral conditions K00–K14 
30100. Unintentional injuries V01–X59, Y40–Y86, Y88, Y89 
30200. Intentional injuries X60–Y09, Y35–Y36, Y870, Y871 
Adapted from Mathers CD at al. (2004). 
Table 2 
Simplified formula for calculating Disability 
Adjusted Life Years – DALY – 
DALY = YLL + YLD 
L 
YLL = ∑ di * ei 
0 
L 
YLD = ∑ Ni * Ii * Ti * D 
0 
YLL, Years of Life Lost; d, number of deaths at each age group; e, 
standard life espectancy at the mean age of death; YLD, Years Lived 
with Disability; N, population susceptible at each age group; I, incidence 
at each age group; T, average duration of disease by age of onset, 
measured in years; D, disability weight (range 0-1, best health = 0, and 
death = 1); L, standard life expectancy for each age and sex obtained 
from Princeton Model Life Table with Level West 26 modified. 
The Spanish population we used was the 
INE estimate as of July 1st, 2006, a total of 
44,068,244 people27. As in the Global 
Burden of Disease study8, 28, we have 
incorporated into the calculations the 
following social value choices: discounting at 
3% (time preference), which makes a present 
benefit more valuable than that same benefit 
obtained in the future, and age-weighting 
(K=1), attributing a higher weight to the 
deaths or disabilities in young adults.  We 
used the Gesmor software package29. 
Research projects analysis and 
distribution of disease-specific funding 
allocated 
The grants given to carry out projects and 
studies through the Promotion of 
Biomedical and Health Sciences Research 
Program in the grant funding opportunities 
call for proposals of the years 2006 and 
2007 within the framework of the Spanish 
National Plan for R&D&I 2004-200730, 31 
were object of the study. Specifically, we 
included: a) research projects32, 33, b) 
research on health services and health 
technology assessment studies34, 35, and c) 
non-commercial clinical research projects 
with drugs intended for human use36. 
We selected the projects that were evaluated 
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and approved in the last two proposal call 
announcements for grant funding, having 
identified them previously in available 
records (HRF data bases). Later, we did a 
systematic review so as to classify the 
projects (and the allocated funds) within each 
group, category and subcategory of the BDC. 
Although the revision and classification 
phase was carried out by epidemiologists, 
expert clinicians’ opinion was needed at 
times. The projects were classified according 
to the title/name of the study, paying 
attention to the main cause of disease. For 
those projects that could be classified into 
more than one cause of disease, funding was 
proportionately distributed among the 
pathologies they involved. Such a criterion 
was valid among the several categories and 
subcategories and has been used in other 
published studies16, 19. 
Finally, the research funds allocated (in 
euros) per DALY lost ratio, was obtained by 
dividing the total funding allocated to the 
research of the several disease 
categories/subcategories by the total DALYs 
lost corresponding to each of them. 
Statistical analysis 
We did a bivariate correlation analysis 
using software SPSS 15.0 with Spearman’s 
non-parametric correlation coefficient (Rho) 
to test the direction and strength of linear 
association between quantitative variables in 
proportional scale (the measures of burden 
of disease and the funding of health 
research). The level of statistical 
significance was established at 0.05 
(confidence level of 95%). 
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RESULTS 
The burden of disease in Spain 2006 
It is estimated that 5,025,472 DALYs 
were lost in Spain in 2006, at a rate of 11,404 
DALYs per 100 thousand inhabitants. Of 
them, 57.7% (2,901,871 YLDs) were caused 
by disability or poor health, and 42.3% 
(2,123,602 YLLs) were due to premature 
death. The leading causes in number of 
DALYs were neuropsychiatric conditions 
(31.8% of the total) coming before malignant 
neoplasms (15.9%), cardiovascular diseases 
(12.3%) or respiratory diseases (7.5%). 
Notable among the diseases subcategories 
causes were the DALY’s weight of unipolar 
depressive disorders (8.8%), dementias 
(7.6%), ischemic heart diseases (4.5%), 
alcohol use disorders (4.1%), lung cancer 
(3.4%) or cerebrovascular disease (2.9%) as 
leading causes of burden of disease (table 3).  
Funding of health research 2006/07 
allocated to the study of diseases 
A total of 1,615 projects were revised, 
87.3% (n=1,410) of which were finally 
included in the analysis. Of them, 3.8% 
(n=53) shared more than one disease 
category/subcategory. Two hundred and five 
(n=205) projects were excluded, because 
they did not aim to study specific diseases. 
According to data provided by the HRF, 
during the study period, 139.6 million euros 
(82.3 million in 2007 and 57.3 million in 
2006) were allocated as grants to undertake 
projects and/or studies, 90.0% (125.6 million 
euros) of which could be included and 
classified in specific disease categories 
(n=21) and subcategories (n=52) (table 3). 
By disease categories, malignant neoplasms, 
neuropsyquiatric conditions, cardiovascular 
diseases and infectious and parasitic diseases 
were the causes to which the largest 
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Table 3 
Burden of disease measures and health research funding by categories 
(n=21) and selected subcategories* (n=52) 






(thousand €) % 
Funds (€) per 
DALY 
Communicable, maternal, 
perinatal and nutricional 
247.7 4.9 133.1 6.3 17.6 4.7 17,474.9 13.9 70.6 
10100 Infectious and parasitic diseases 113.7 2.3 66.9 3.1 7.4 2.0 12,344.9 9.8 108.6 
HIV/AIDS 36.9 0.7 28.1 1.3 1.4 0.4 4,026.5 3.2 109.1 
Diarrhoeal diseases 11.5 0.2 1.5 0.1 0.4 0.1 975.4 0.8 84.8 
Hepatitis B and C 10.3 0.2 8.9 0.4 1.0 0.3 974.4 0.8 95.0 
STD 8.9 0.2 0.2 0.0 0.0 0.0 22.6 0.0  2.5 
Meningitis 4.9 0.1 3.0 0.1 0.2 0.1 277.1 0.2 56.2 
Tuberculosis 4.6 0.1 2.9 0.1 0.4 0.1 840.4 0.7 182.0 
10200 Respiratory infections 36.6 0.7 31.6 1.5 8.8 2.4 2,215.5 1.8 60.6 
Lower respiratory infect. 32.7 0.7 31.3 1.5 8.8 2.4 1,693.4 1.3 51.7 
Otitis media 3.2 0.1 0.0 0.0 0.0 0.0 36.3 0.0 11.3 
Upper respiratory infect. 0.6 0.0 0.3 0.0 0.1 0.0 6.1 0.0 10.0 
10300 Maternal conditions 18.2 0.4 0.4 0.0 0.0 0.0 1,569.5 1.2 86.3 
10400 Perinatal conditions 49.2 1.0 33.2 1.6 1.0 0.3 958.5 0.8 19.5 
10500 Nutritional deficiencies 30.1 0.6 1.1 0.1 0.3 0.1 386.5 0.3 12.8 
Non communicable 4,441.0 88.4 1,748.8 82.4 337.8 90.9 107,085.1 85.2 24.1 
20100 Malignant neoplasms 797.7 15.9 720.2 33.9 101.0 27.2 26,992.3 21.5 33.8 
Lung 171.4 3.4 166.4 7.8 21.1 5.7 1,008.7 0.8 5.9 
Colon and rectum 101.3 2.0 84.0 4.0 14.3 3.8 1,865.1 1.5 18.4 
Breast 70.6 1.4 58.2 2.7 6.6 1.8 3,856.6 3.1 54.6 
Stomach 42.4 0.8 40.6 1.9 6.2 1.7 466.5 0.4 11.0 
Pancreas 37.9 0.8 36.9 1.7 5.3 1.4 464.6 0.4 12.3 
Lymphoma, myeloma 33.7 0.7 31.9 1.5 4.5 1.2 1,508.3 1.2 44.8 
Liver 32.5 0.6 31.9 1.5 4.8 1.3 646.3 0.5 19.9 
Bladder 31.9 0.6 25.2 1.2 4.9 1.3 942.7 0.8 29.5 
Brain 30.7 0.6 29.9 1.4 2.7 0.7 1,133.7 0.9 37.0 
Leukaemia 28.9 0.6 27.6 1.3 3.4 0.9 2,149.6 1.7 74.5 
Prostate 27.5 0.5 21.8 1.0 5.8 1.6 813.5 0.6 29.6 
Mouth, oropharynx 23.9 0.5 22.3 1.1 2.3 0.6 80.3 0.1  3.4 
Ovary 19.1 0.4 16.8 0.8 1.9 0.5 444.6 0.4 23.3 
Corpus uteri 19.1 0.4 9.5 0.4 1.5 0.4 451.4 0.4 23.6 
Oesophagus 16.5 0.3 16.0 0.8 1.9 0.5  7.0 0.1  4.4 
Kidney 15.9 0.3 14.7 0.7 2.1 0.6 233.3 0.2 14.7 
Larynx 14.6 0.3 13.7 0.6 1.7 0.4 93.8 0.1  6.4 
Melanoma 11.9 0.2 11.0 0.5 1.4 0.4 909.7 0.7 76.6 
Cervix uteri 9.5 0.2 7.7 0.4 0.7 0.2 936.0 0.7 98.7 
Bone and cartilage 5.8 0.1 5.5 0.3 0.3 0.1 200.6 0.2 34.7 
Thyroid 2.0 0.0 1.8 0.1 0.3 0.1 73.2 0.1 37.1 
20200 Other neoplasms 21.4 0.4 21.4 1.0 3.5 0.9 182.1 0.1  8.5 
20300 Diabetes mellitus 84.4 1.7 39.3 1.8 10.0 2.7 2,726.7 2.2 32.3 
20400 Endocrine & blood disorders 59.5 1.2 19.4 0.9 2.8 0.8 6,863.9 5.5 115.3 
20500 Neuropsychiatric conditions 1,599.5 31.8 110.9 5.2 28.7 7.7 21,248.7 16.9 13.3 
Unipolar depression 444.7 8.8 0.2 0.0 0.1 0.0 1,779.5 1.4 4.0 
Dementias 381.3 7.6 56.0 2.6 21.9 5.9 2,473.8 2.0 6.5 
Alcohol use disorders 208.4 4.1 3.6 0.2 0.3 0.1 31.8 0.0 0.2 
Migraine 79.6 1.6 0.0 0.0 0.0 0.0 222.0 0.2 2.8 
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Table 3 (continued) 
Burden of disease measures and health research funding by categories 
(n=21) and selected subcategories* (n=52) 






(thousand €) % 
Funds (€) per 
DALY 
20500 Drug use disorders 70.0 1.4 2.3 0.1 0.1 0.0 1,423.6 1.1 20.3 
Bipolar disorders 68.3 1.4 0.1 0.0 0.0 0.0 198.9 0.2  2.9 
Schizophrenia 64.1 1,3 1.0 0.0 0.1 0.0 2,291.3 1.8 35.8 
Parkinson disease 30.2 0.6 8.5 0.4 2.6 0.7 979.4 0.8 32.4 
Obsessive-compulsive 
disorder 28.7 0.6 0.0 0.0 0.0 0.0 362.5 0.3 12.6 
Epilepsy 13.9 0.3 4.8 0.2 0.4 0.1 290.2 0.2 20.9 
Multiple sclerosis 10.1 0.2 2.3 0.1 0.2 0.0 945.8 0.8 93.2 
20600 Sense organ disorders 260.0 5.2 0.0 0.0 0.0 0.0 3,704.8 2.9 14.3 
Glaucoma 11.1 0.2 0.0 0.0 0.0 0.0 269.8 0.2 24.3 
20700 Cardiovascular diseases 618.2 12.3 517.9 24.4 124.8 33.6 19,865.8 15.8 32.1 
Ischaemic heart disease 227.0 4.5 194.5 9.2 38.5 10.4 3,651.3 2.9 16.1 
Cerebrovascular disease 145.1 2.9 130.3 6.1 34.0 9.2 2,947.1 2.3 20.3 
Inflammatory heart disease 50.2 1.0 30.4 1.4 6.3 1.7 777.8 0.6 15.5 
Hypertensive disease 26.1 0.5 21.2 1.0 6.9 1.9 658.9 0.5 25.2 
20800 Respiratory diseases 377.4 7.5 123.7 5.8 31.7 8.5 5,822.2 4.6 15.4 
COPD 114.4 2.3 56.8 2.7 16.6 4.5 2,418.4 1.9 21.1 
Asthma 67.4 1.3 4.0 0.2 0.8 0.2 1,036.8 0.8 15.4 
20900 Digestive diseases 225.9 4.5 120.8 5.7 20.0 5.4 6,475.0 5.2 28.7 
Cirrhosis 61.4 1.2 49.6 2.3 4.9 1.3 2,336.9 1.9 38.0 
21000 Genito-urinary diseases 63.8 1.3 33.0 1.6 9.7 2.6 3,819.8 3.0 59.9 
Nephritis, nephrosis 24.3 0.5 23.1 1.1 6.6 1.8 2,270.3 1.8 93.4 
21100 Skin diseases 10.4 0.2 3.4 0.2 1.1 0.3 182.0 0.1 17.5 
21200 Muskuloskeletal diseases  234.8  4.7  11.4  0.5  3.5  0.9  4.394.1  3.5  18.7 
Osteoarthritis 124.0 2.5 0.2 0.0 0.1 0.0 549.6 0.4  4.4 
Rheumatoid arthritis 41.5 0.8 1.2 0.1 0.2 0.1 1,458.7 1.2 35.1 
21300 Congenital anomalies 49.3 1.0 27.2 1.3 1.0 0.3 4,726.5 3.8 95.8 
21400 Oral conditions 38.8 0.8 0.1 0.0 0.0 0.0 81.3 0.1 2.1 
Accidents and injuries 336.8 6.7 241.6 11.4 16.1 4.3 1,066.1 0.8 3.2 
30100 Unintentional injuries 268.9 5.4 180.7 8.5 12.5 3.4 760.8 0.6 2.8 
30200 Intentional injuries 67.8 1.3 60.9 2.9 3.6 1.0 305.4 0.2 4.5 
Total 5,025.5 100 2,123.6 100 371.5 100 125,626.2 100 25.0 
* The subcategories shown do not include all of the diseases in each category, and therefore do not add up to 100% of their corresponding category. 
DALY, Disability-Adjusted Life Years; YLL, Years of Life Lost; Mortality, as the number of deaths by cause; HIV/AIDS, Human Immunodeficiency 
Virus – Acquired Immunodeficiency Syndrome; STD, Sexually Transmitted Diseases; COPD, Chronic Obstructive Pulmonary Disease. 
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Figure 1 
Scatter-plot representing Disability Adjusted Life Years and research funding  


















Scatter-plot representing Years of Life Lost and research funding  
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proportion of budget was allocated (64.0% of 
the total). The subcategories that received 
more funding were HIV/AIDS (3.2%), breast 
cancer (3.1%), ischemic heart disease (2.9%) 
and cerebrovascular disease (2.3%). Among 
the selected causes for this study, upper 
respiratory infections, sexually transmitted 
diseases and alcohol use disorders were the 
subcategories with less funding in the 
analyzed period. 
Association between the burden of 
disease and health research funding 
By disease categories, a high correlation 
was observed between funding and disease 
burden measures with a positive association 
at the level of statistical significance applied 
(figures 1-2). The correlation between the 
research funds and the DALYs 
was 0.72 (p<0.001), being this the highest 
correlation we found. Likewise, an 
association was found for other indicators 
such as YLLs and proportional mortality, 
with correlations of 0.56 (p=0.008) and 
0.60 (p=0.004), respectively. The analysis 
of the main disease subcategories also 
showed a positive association (figure 3), 
moderate and statistically significant: 0.54 
(p<0.001) for proportional mortality, and 
0.55 (p<0.001) for DALYs and YLLs. 
Endocrine and blood disorders, infectious 
and parasitic diseases and congenital 
anomalies were the disease categories that 
most financing received per each DALY 
lost (see table 3). By subcategories, it is 
worth mentioning that tuberculosis, 
HIV/AIDS, cervix uteri cancer, hepatitis B 
C, nephritis and nephrosis and multiple 
Figure 3 
Scatter-plots representing disease-burden measures and research funding by 52 disease specific 
subcategories 
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sclerosis were the specific causes with 
most funds allocated per DALY lost. 
On the contrary, some neuropsychiatric 
conditions (e.g. alcohol use disorders, 
migraine, bipolar affective disorders, 
unipolar depressive disorders), some 
specific cancers (e.g. mouth, 
pharyngoesophageal, lung cancer), 
unintentional injuries or sexually 
transmitted diseases, were the causes that 
had the lowest research fund allocated 
per DALY lost ratios. 
DISCUSSION 
According to the current Spanish 
National Plan for R&D&I 2008-20113 and 
to the Quality Plan for the NHS37, in Spain, 
the burden of disease should be a criterion 
for setting priorities in the NHS. This is the 
first study carried out in the Spanish NHS 
ambit that evaluates results of the setting of 
priorities in objective methods of burden of 
disease assessment, which has permitted 
observing the existence of a positive 
moderately high-association between these 
health outcomes measures and the research 
funding from the ISCIII. These results 
would be in keeping with earlier studies 
done in countries such as the U.S.16, 17 
(National Institutes of Health – NIH, 
Centers for Disease Control and Prevention 
– CDC), Canada18 (Medical Research 
Council of Canada – MRCC), Australia19 
(National Health and Medical Research 
Council – NHMRC) or United Kingdom20, 
21 (National Cancer Research Institute – 
NCRI, UK Clinical Research Collaboration 
– UKCRC), although the different periods 
studied and some methodological 
differences makes difficult a direct 
comparison between works. 
Planning in research is a complex, 
dynamic and evaluable process in which 
clinical, epidemiological, socio-economic, 
political, and other factors meet. So as to 
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set priorities, one can resort mainly to two 
types of approach38 : technical assessments 
through epidemiological or socio-economic 
data using quantitative methods (e.g. 
burden of disease studies), and subjective 
approximations based on implicit 
evaluations from peer reviewers using 
qualitative consensus methods or other 
group techniques, consulting with key 
agents, etc39. Each of the methods 
suggested in the literature has its pros and 
cons, but “the transparency and 
corresponsibility in the process are 
favoured if the criteria are explicit and the 
several agents involved: politicians, 
professionals, researchers, patients and 
citizens, are committed”40. Generally, the 
actions relating to these processes require 
the awareness of the population health 
status. The information from the burden of 
disease studies make possible that funds are 
allocated to predetermined goals using a 
concrete and, in our opinion, solid 
methodology from a public health point of 
view. 
While the information from these studies 
can be used as measurement unit of health 
outcomes in explicit cost-effectiveness (or 
cost-utility) analyses, the burden of disease 
on its own does not permit the measurement 
of the efficiency of the short-medium term 
allocation of resources to research. 
Therefore, the fact that the burden of 
disease is larger for one condition does not 
necessarily imply larger health benefits 
allocating more resources, in the same way 
that the existence of effective health 
interventions does not guarantee a better 
use of them in terms of effectiveness, 
efficiency or equity and accessibility to 
health services. Therefore, it would be 
convenient to consider some of these 
variables as well as the potential gains 
attributed to research, the use of number of 
DALYs or other alternative indices being a 
possibility for doing this41, 42. Despite the 
limitations and difficulties in the 
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measurement of these results, the 
explanation of some of these aspects could 
contribute to a better understanding of the 
research carried out in the NHS. In 
economic terms, marginal productivity of 
the investments in research and innovation 
could also be an aspect to consider. 
In other published analyses, where the 
range of variation in the data was wide, the 
variables transformation to logarithmic 
scales was proposed, and fit tests for 
normality were used in the variables 
distribution with the intention of applying a 
regression analysis that would allow the 
obtention of projections based on observed 
values to set future funding needs, assuming 
the adoption of the burden of disease as the 
only criterion in the decisions on funding. 
This last point transcends the goals of this 
particular study, which limited itself to 
correlate the relative distributions of both 
variables, funding and burden of disease, 
although the methods suggested by other 
authors16, 17 will be applied in future 
analyses to identify needs in specific disease 
categories or topic areas and to provide with 
complementary information for the setting 
of priorities on the allocation and 
reorientation of research funds. 
Some of the limitations of these studies 
have to do with refer to the parameters used 
for the calculation of DALYs, such as social 
preferences to establish the disability 
weight, the discount rate to be applied and 
the weighting of years as a function of age. 
The grounds for the inclusion of these 
parameters have been widely debated in the 
scientific literature43-47. An uncertainty 
assessment for these variables was done by 
means of a sensitivity analysis based on the 
recommendations given by the WHO in the 
Global Burden of Disease study8, 28. This 
permitted testing the robustness of the 
burden of disease model faced with changes 
in parameters such as the discounting (e.g. 
without applying discounting) and the age­
weighting (e.g. without weighting; K=0). 
The analyses of DALYs estimated for the 
Spanish population along with the funding 
permits stating that there are groups of 
categories that receive more funds than 
burden they generate. Generally speaking, 
these coincide with the main causes of 
mortality. Such is the case, for instance, of 
malignant neoplasms and cardiovascular 
diseases, which represent 28.2% of burden 
of disease and 37.7% of funding. A similar 
situation occurs with infectious and parasitic 
diseases (2.3% of the total DALYs) or 
endocrine and blood disorders (1.2% of 
DALYs), with 9.8% and 5.5% of funding 
respectively. Quite the opposite occurs with 
neuropsychiatric conditions, first cause of 
burden of disease (31.8% of total DALYs), 
where disability or poor health are much 
higher than mortality (6.9% YLLs), and to 
which, despite being the second category in 
receiving the most funding, only 16.9% of 
the total funding was allocated. 
With reference to research funding in the 
NHS, excluding research financed by the 
pharmaceutical and health products industry, 
funding comes mostly from the ISCIII 
which works as a funding organization 
through the HRF. In our opinion, the 
activities object of this study can be 
considered representative of the health 
research promotion measures carried out by 
the NHS, although it would be interesting to 
increase the number of call announcements 
opportunities for these grants in the future, 
or grants that go to the promotion and 
strengthening of the stable cooperative 
research structures and biomedical research 
network centers, also other budget items that 
would incorporate actions other than those 
specifically aimed at the NHS (e.g. 
fundamental research projects, applied 
research projects, innovation projects, etc.) 
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that are included in other programs of the 
Spanish National Plan for R&D&I2, 3 as well 
as the need for analyses of the distribution of 
funding by topic areas (basic, clinical or in 
epidemiology and public health research). 
There are other types of grant funding 
opportunities that have not been considered 
here (e.g. grants given by the Spanish 
Regional Governments, European programs 
or other grants coming from public and 
private non-profit organizations, etc.). This 
last point leads us to a new consideration. 
The explicit understanding of how these 
actions, along with those that are carried out 
from the private sector, influence the NHS’s 
capacity of attaining its goals, and of how the 
cross-sector relations or agreements can give 
rise to several interactions, must be object of 
reflection, arising the following question: 
Should public funding adjust itself to the 
DALYs distribution or should it be the 
totality of the research in the public and 
private sectors which does that? Or, indeed: 
To which extent should public funding cover 
the research and innovation considered as a 
social priority but to which the market is not 
able to allocate funding because it perceives 
that the potential gains do not justify the 
opportunity cost of the investment? Such 
point could be the case of topic areas that are 
overlooked, poorly developed or present 
among traditionally disadvantaged 
population groups (e.g. rare diseases, some 
infectious and parasitic diseases, the 
paediatric population, etc.). 
The world integration or globalization that 
has been accelerating for the past decades is 
another aspect worthy of consideration since, 
logically, it also affects health research. As 
the integration grows, technological progress 
accelerates. In fact, the research and 
development of innovative health 
interventions carried out by countries with 
stable scientific and technological policies is 
allowing other countries’ populations to 
improve their health and welfare. 
Finally, in the light of the methodological 
and practical limitations that can be present 
in this study, it seems necessary to insist on 
the convenience of keeping to the initiated 
line of work, fostering the collaboration and 
consensus among all agents involved. It is 
difficult to set priorities on the basis of a 
single criterion because of the already 
mentioned complexities. Burden of disease 
studies let us present the dimension of a 
population’s health problems, provide 
knowledge about the relative and absolute 
importance of diseases and, therefore, 
contribute to the setting of priorities. It is 
worth recalling that there are other criteria 
(e.g. quality of the proposals, relevance of 
the projects, value of transfer to clinical 
practice, structure and quality of the research 
team, scientific opportunities, etc.) that also 
will have to be taken into account by 
decision-makers, managers and evaluators in 
their decision making. 
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